









Markets
/
Stocks
/
nasdaq-rptx
/

Repare Therapeutics Inc

RPTX

1.710USD

-0.055-3.12%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

73.46MMarket Cap

LossP/E TTM



Repare Therapeutics Inc

1.710

-0.055-3.12%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

132 / 506

Overall Ranking

239 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

5.000

Target Price

+183.29%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.

Growing

The company is in a growing phase, with the latest annual income totaling USD 53.48M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 191.56.

Overvalued

The company’s latest PE is -0.66, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 30.95M shares, decreasing 24.59% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 522.86K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.68.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.63, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 250.00K, representing a year-over-year decrease of 76.70%, while its net profit experienced a year-over-year decrease of 51.85%.

Score

Industry at a Glance

Previous score

7.63

Change



Financials

9.47

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.08

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

3.06

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.55

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.68, which is 145.40% below the recent high of -1.68 and -1931.89% above the recent low of -13.90.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 132/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.33, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Repare Therapeutics Inc is 5.00, with a high of 5.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

5.000

Target Price

+183.29%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Repare Therapeutics Inc

RPTX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 5.03, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.89 and the support level at 1.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.03

Change

-0.24

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.009

Neutral

RSI(14)

55.021

Neutral

STOCH(KDJ)(9,3,3)

33.636

Sell

ATR(14)

0.067

Low Volatility

CCI(14)

-4.249

Neutral

Williams %R

48.038

Neutral

TRIX(12,20)

0.514

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

1.744

Sell

MA10

1.749

Sell

MA20

1.703

Buy

MA50

1.601

Buy

MA100

1.504

Buy

MA200

1.447

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 72.17%, representing a quarter-over-quarter decrease of 6.64%. The largest institutional shareholder is James Simons, holding a total of 522.86K shares, representing 1.22% of shares outstanding, with 48.92% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BVF Partners L.P.

10.33M

Blue Owl Capital Holdings LP

3.37M

-2.07%

OrbiMed Advisors, LLC

3.20M

-3.68%

Versant Ventures

2.97M

+12.13%

Redmile Group, LLC

1.88M

-1.65%

MPM Capital Inc.

1.12M

-42.24%

Citadel Advisors LLC

937.49K

MPM BioImpact LLC

819.92K

-33.40%

Acadian Asset Management LLC

640.33K

+35.63%

Renaissance Technologies LLC

Star Investors

298.66K

-14.04%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.04, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.07. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.